Targeting glycolysis with inhibitors of HK2, LDHA, or PKM2 has shown promise in preclinical models, indicating that disrupting glycolytic flux could be a therapeutic strategy in MYC-driven medulloblastoma [32]. This evidence concerns the gene MYC and medulloblastoma.